AU2014228307A1 - Bimatoprost for enhancement of leptin production - Google Patents

Bimatoprost for enhancement of leptin production

Info

Publication number
AU2014228307A1
AU2014228307A1 AU2014228307A AU2014228307A AU2014228307A1 AU 2014228307 A1 AU2014228307 A1 AU 2014228307A1 AU 2014228307 A AU2014228307 A AU 2014228307A AU 2014228307 A AU2014228307 A AU 2014228307A AU 2014228307 A1 AU2014228307 A1 AU 2014228307A1
Authority
AU
Australia
Prior art keywords
bimatoprost
administered
leptin
human
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014228307A
Other languages
English (en)
Inventor
Robert M. Burk
Grantley CHARLES
Michael E. Garst
Suzanne Kanaly
Timothy J. Maziasz
Neil J. POLOSO
David F. Woodward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AU2014228307A1 publication Critical patent/AU2014228307A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2014228307A 2013-03-15 2014-03-13 Bimatoprost for enhancement of leptin production Abandoned AU2014228307A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361793132P 2013-03-15 2013-03-15
US61/793,132 2013-03-15
PCT/US2014/026110 WO2014143629A1 (en) 2013-03-15 2014-03-13 Bimatoprost for enhancement of leptin production

Publications (1)

Publication Number Publication Date
AU2014228307A1 true AU2014228307A1 (en) 2015-09-10

Family

ID=50442712

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014228307A Abandoned AU2014228307A1 (en) 2013-03-15 2014-03-13 Bimatoprost for enhancement of leptin production

Country Status (11)

Country Link
US (2) US20140275272A1 (cg-RX-API-DMAC10.html)
EP (1) EP2968361A1 (cg-RX-API-DMAC10.html)
JP (1) JP2016513647A (cg-RX-API-DMAC10.html)
KR (1) KR20150129735A (cg-RX-API-DMAC10.html)
CN (1) CN105338985A (cg-RX-API-DMAC10.html)
AU (1) AU2014228307A1 (cg-RX-API-DMAC10.html)
BR (1) BR112015021859A2 (cg-RX-API-DMAC10.html)
CA (1) CA2901529A1 (cg-RX-API-DMAC10.html)
HK (1) HK1220385A1 (cg-RX-API-DMAC10.html)
RU (1) RU2015134772A (cg-RX-API-DMAC10.html)
WO (1) WO2014143629A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102159427B1 (ko) 2015-04-30 2020-09-24 알러간, 인코포레이티드 지방 감소를 위한 미용적 방법 및 치료적 용도
WO2026072679A1 (en) * 2024-09-25 2026-04-02 Manistee Therapeutics Inc. Methods and compositions for the delivery of prostaglandin f2a analogs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO2007111806A2 (en) * 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
RU2482851C2 (ru) * 2009-02-20 2013-05-27 Микро Лабс Лимитед Хранение стабильного продукта простагландина
CA2824317C (en) * 2011-01-19 2014-12-16 Terakine Therapeutics, Inc. Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia

Also Published As

Publication number Publication date
RU2015134772A (ru) 2017-04-21
CN105338985A (zh) 2016-02-17
WO2014143629A1 (en) 2014-09-18
US20160310505A1 (en) 2016-10-27
BR112015021859A2 (pt) 2017-07-18
US20140275272A1 (en) 2014-09-18
EP2968361A1 (en) 2016-01-20
CA2901529A1 (en) 2014-09-18
JP2016513647A (ja) 2016-05-16
KR20150129735A (ko) 2015-11-20
RU2015134772A3 (cg-RX-API-DMAC10.html) 2018-03-21
HK1220385A1 (zh) 2017-05-05

Similar Documents

Publication Publication Date Title
CN101198362B (zh) 在癌症化疗和放疗时保护细胞的局部血管收缩剂制品和方法
US7682623B2 (en) Pharmaceutical composition for topical application
EP3744330B1 (en) Reduction of adipose tissue
US8512718B2 (en) Pharmaceutical composition for topical application
KR101533695B1 (ko) 피부 외용제 조성물
JP5897164B2 (ja) 外用組成物
US20230148647A1 (en) Composition for promoting biosynthesis of elastin and collagen in connective tissue
US20240315985A1 (en) Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitis
US20160310505A1 (en) Prostamides for enhancement of leptin production
EP1448208B1 (fr) Composition a base d'ester de diosgenine applicable par voie topique
CN1960723B (zh) 烷基呋喃在制备用于治疗肥胖症的药物中的用途
KR102937906B1 (ko) 건선의 예방, 개선 또는 치료용 조성물
JPWO2020175131A1 (ja) 脈管異常治療用外用剤
JP7025129B2 (ja) 筋痙攣治療剤
HK40065012A (en) Methods and formulations for transdermal administration
KR20140037045A (ko) 치료적 쿨링제 조성물에서 용매로서 사용하기 위한 (r)-1,2-프로판디올
AU2017279578A1 (en) Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application